SYDNEY–(BUSINESS WIRE)–DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an
Month: October 2026
Your investment could be affected by this vote. No matter how many shares you hold – vote today
DELTA, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, is pleased to announce that it has filed and commenced mailing of its Management Information Circular (the “Circular”) and related materials in connection with the Company’s upcoming Annual General Meeting of Shareholders (the “Meeting”). The Circular is now available under RecycLiCo’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at https://recyclico.com/annual-general-meeting.
Meeting Details
The Annual General Meeting of shareholders will be held on Tuesday, November 17, 2026, at 1:00 p.m. (Vancouver time) at:
RecycLiCo Battery Materials Inc.
Board Room, 110 – 7858 Hoskins Street
Delta, British Columbia V4G 1M4
Register for Zoom link: 2026 RecycLiCo Annual General Meeting
The Board of Directors unanimously recommends that shareholders vote FOR all proposed items outlined in the Circular.
The deadline to vote your shares is Friday, November 13, 2026, at 1:00 p.m. (Vancouver time). Shareholders are encouraged to review the Circular and submit their votes as soon as possible.
Shareholder Questions
Shareholders who have questions or require assistance with voting may contact the Company’s transfer agent, Endeavor Trust Corporation:
Toll-Free: 1-888-787-0888
Email: proxy@EndeavorTrust.com
About RecycLiCo
RecycLiCo Battery Materials Inc. is a critical minerals refining company specializing in the use of advanced hydrometallurgical technologies for processing mined ore and the upcycling of lithium-ion battery materials. RecycLiCo’s processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage as well as broader industrial applications. RecycLiCo’s business focus aligns with the global demand for future-ready, responsible supply chains and the growing movement to strengthen domestic sourcing of critical materials.
For more information, please contact:
Paola Ashton
PRA Communications
Telephone: 604-681-1407
Email: pashton@pracommunications.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.
Your investment could be affected by this vote. No matter how many shares you hold – vote today
DELTA, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, is pleased to announce that it has filed and commenced mailing of its Management Information Circular (the “Circular”) and related materials in connection with the Company’s upcoming Annual General Meeting of Shareholders (the “Meeting”). The Circular is now available under RecycLiCo’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at https://recyclico.com/annual-general-meeting.
Meeting Details
The Annual General Meeting of shareholders will be held on Tuesday, November 17, 2026, at 1:00 p.m. (Vancouver time) at:
RecycLiCo Battery Materials Inc.
Board Room, 110 – 7858 Hoskins Street
Delta, British Columbia V4G 1M4
Register for Zoom link: 2026 RecycLiCo Annual General Meeting
The Board of Directors unanimously recommends that shareholders vote FOR all proposed items outlined in the Circular.
The deadline to vote your shares is Friday, November 13, 2026, at 1:00 p.m. (Vancouver time). Shareholders are encouraged to review the Circular and submit their votes as soon as possible.
Shareholder Questions
Shareholders who have questions or require assistance with voting may contact the Company’s transfer agent, Endeavor Trust Corporation:
Toll-Free: 1-888-787-0888
Email: proxy@EndeavorTrust.com
About RecycLiCo
RecycLiCo Battery Materials Inc. is a critical minerals refining company specializing in the use of advanced hydrometallurgical technologies for processing mined ore and the upcycling of lithium-ion battery materials. RecycLiCo’s processes efficiently recover battery-ready lithium, cobalt, nickel, and manganese from end-of-life batteries and manufacturing scrap, supporting energy storage as well as broader industrial applications. RecycLiCo’s business focus aligns with the global demand for future-ready, responsible supply chains and the growing movement to strengthen domestic sourcing of critical materials.
For more information, please contact:
Paola Ashton
PRA Communications
Telephone: 604-681-1407
Email: pashton@pracommunications.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced that the University of California, Davis (UC Davis), has been activated as a clinical trial site for CERTAIN-T, the Company’s ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236.
The activation of UC Davis is expected to expand patient recruitment capacity while leveraging the site’s existing manufacturing capabilities to streamline treatment logistics.
Brian Jonas, M.D., Professor, clinician-scientist, and Chief of the Division of Malignant Hematology, Cellular Therapy and Transplantation in the Department of Internal Medicine at the UC Davis School of Medicine and UC Davis Comprehensive Cancer Center and study investigator on the trial, commented, “We are excited to join with CERo Therapeutics to open this important clinical trial. We look forward to being able to offer a novel and innovative chimeric engulfment receptor-based treatment option for our patients with myeloid malignancies.”
Chris Ehrlich, CERo Therapeutics CEO added, “The addition of UC Davis represents another important milestone in our collaboration, expanding our longstanding relationship beyond manufacturing to include patient enrollment in the CERTAIN-T study. Integrating manufacturing and clinical operations at a single institution has the potential to expand patient access while shortening the time between cell manufacturing and patient infusion. We have been encouraged by the interest we’ve received from investigators and institutions evaluating participation in the CERTAIN-T trial, and we are pleased to welcome the UC Davis team.”
CERo previously reported findings from six patients treated in the first two cohorts of CERTAIN-T. All three patients in the second cohort completed the 28-day dose-limiting toxicity assessment without a DLT. In its June 2026 update, the Company reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. Preliminary investigator observations noted clinical improvement in two patients; however, formal response assessments remain ongoing, are based on a limited number of patients, and no definitive safety or efficacy conclusions can be drawn at this time. One patient with refractory AML subsequently underwent allogeneic stem cell transplantation 71 days after CER-1236 infusion. The study protocol has been amended to include MDS and myelofibrosis.
About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, AML with measurable residual disease (MRD), and newly diagnosed TP53-mutated AML, and the protocol has since been amended to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).
The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and the Company’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. CERo undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced that the University of California, Davis (UC Davis), has been activated as a clinical trial site for CERTAIN-T, the Company’s ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236.
The activation of UC Davis is expected to expand patient recruitment capacity while leveraging the site’s existing manufacturing capabilities to streamline treatment logistics.
Brian Jonas, M.D., Professor, clinician-scientist, and Chief of the Division of Malignant Hematology, Cellular Therapy and Transplantation in the Department of Internal Medicine at the UC Davis School of Medicine and UC Davis Comprehensive Cancer Center and study investigator on the trial, commented, “We are excited to join with CERo Therapeutics to open this important clinical trial. We look forward to being able to offer a novel and innovative chimeric engulfment receptor-based treatment option for our patients with myeloid malignancies.”
Chris Ehrlich, CERo Therapeutics CEO added, “The addition of UC Davis represents another important milestone in our collaboration, expanding our longstanding relationship beyond manufacturing to include patient enrollment in the CERTAIN-T study. Integrating manufacturing and clinical operations at a single institution has the potential to expand patient access while shortening the time between cell manufacturing and patient infusion. We have been encouraged by the interest we’ve received from investigators and institutions evaluating participation in the CERTAIN-T trial, and we are pleased to welcome the UC Davis team.”
CERo previously reported findings from six patients treated in the first two cohorts of CERTAIN-T. All three patients in the second cohort completed the 28-day dose-limiting toxicity assessment without a DLT. In its June 2026 update, the Company reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. Preliminary investigator observations noted clinical improvement in two patients; however, formal response assessments remain ongoing, are based on a limited number of patients, and no definitive safety or efficacy conclusions can be drawn at this time. One patient with refractory AML subsequently underwent allogeneic stem cell transplantation 71 days after CER-1236 infusion. The study protocol has been amended to include MDS and myelofibrosis.
About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, AML with measurable residual disease (MRD), and newly diagnosed TP53-mutated AML, and the protocol has since been amended to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).
The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and the Company’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. CERo undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact:
Chris Ehrlich
Chief Executive Officer
chris@cero.bio
Investors:
CORE IR
investors@cero.bio
HOUSTON–(BUSINESS WIRE)–NRG Energy, Inc. (NYSE:NRG) plans to report its third quarter 2026 financial results on Monday, November 9, 2026. Management will present the results during a conference call and webcast at 8:00 a.m. EST (7:00 a.m. CST). The company will issue a press release regarding the third quarter 2026 financial results prior to the conference call, and it will be available on the NRG website at www.nrg.com. The live webcast and presentation materials can be accessed at investors
HOUSTON–(BUSINESS WIRE)–NRG Energy, Inc. (NYSE:NRG) plans to report its third quarter 2026 financial results on Monday, November 9, 2026. Management will present the results during a conference call and webcast at 8:00 a.m. EST (7:00 a.m. CST). The company will issue a press release regarding the third quarter 2026 financial results prior to the conference call, and it will be available on the NRG website at www.nrg.com. The live webcast and presentation materials can be accessed at investors
THE WOODLANDS, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — TWFG, Inc. (NASDAQ: TWFG), a leading independent insurance distribution platform, announced today that it will release its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.
The Company will host a conference call to discuss its financial results at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Wednesday, November 4, 2026.
CLICK HERE TO ACCESS THE CALL BY WEBCAST
TO REGISTER FOR ACCESS TO THE LIVE CONFERENCE CALL:
- Click on the link below and complete the online registration form.
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call:
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
A replay of the webcast will be available on the Investor Relations website for a limited time following the call.
About TWFG
TWFG, Inc. (NASDAQ: TWFG) is a leading insurance distribution platform providing innovative and personalized insurance solutions to individuals and businesses across the United States. Anchored by a scalable, technology-enabled platform, TWFG supports a sophisticated agent network of retail branch agencies, and MGA agents, that create sustainable growth and long-term value. For more information, visit www.twfg.com.
For more information, please contact:
Investor Contact:
ir@twfg.com
PR Contact:
Alex Bunch
TWFG, Inc. – Chief Marketing Officer
E-mail: alex@twfg.com
THE WOODLANDS, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) — TWFG, Inc. (NASDAQ: TWFG), a leading independent insurance distribution platform, announced today that it will release its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.
The Company will host a conference call to discuss its financial results at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Wednesday, November 4, 2026.
CLICK HERE TO ACCESS THE CALL BY WEBCAST
TO REGISTER FOR ACCESS TO THE LIVE CONFERENCE CALL:
- Click on the link below and complete the online registration form.
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call:
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
A replay of the webcast will be available on the Investor Relations website for a limited time following the call.
About TWFG
TWFG, Inc. (NASDAQ: TWFG) is a leading insurance distribution platform providing innovative and personalized insurance solutions to individuals and businesses across the United States. Anchored by a scalable, technology-enabled platform, TWFG supports a sophisticated agent network of retail branch agencies, and MGA agents, that create sustainable growth and long-term value. For more information, visit www.twfg.com.
For more information, please contact:
Investor Contact:
ir@twfg.com
PR Contact:
Alex Bunch
TWFG, Inc. – Chief Marketing Officer
E-mail: alex@twfg.com
MONACO DI BAVIERA e LOS ANGELES–(BUSINESS WIRE)–Per la prima volta nella storia delle Olimpiadi e delle Paralimpiadi, un impianto di gara porterà il nome Allianz. L’Allianz Beach Arena di Long Beach, in California, che ospiterà i Giochi Olimpici e Paralimpici LA28, diventerà il nuovo membro della Famiglia di stadi Allianz. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lett